| 查看: 409 | 回复: 1 | |||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | |||
cainiaodui新虫 (小有名气)
|
[求助]
翻译求助
|
||
| Although Notch inhibitors are still preclinical, the monoclonal VEGF antibody bevacizumab is clinically available and represents a potential for combination therapy. As discussed above, some tumors are responsive to VEGF inhibition, although others are unresponsive and become resistant over time.This is most likely due to compensation by other angiogenic pathways that maintain the tumor vasculature. In patients with metastatic breast cancer, treatment with anti-VEGF therapy did not show a statistically significant increase in overall survival benefit.However, combination anti-angiogenic therapy may be useful in overcoming this resistance. |
回复此楼» 猜你喜欢
材料与化工371求调剂
已经有9人回复
-
085600调剂
已经有9人回复
-
346分的生物与医药08600求调剂
已经有6人回复
-
304求调剂（085602，过四级，一志愿985）
已经有13人回复
-
328分调剂
已经有6人回复
-
求调剂
已经有9人回复
-
358求调剂
已经有7人回复
-
生物与医药调剂
已经有3人回复
-
367求调剂
已经有3人回复
-
工科08专硕机械275求调剂
已经有3人回复
RXMCDM
版主 (文坛精英)
- 翻译EPI: 530
- 应助: 401 (硕士)
- 贵宾: 1.908
- 金币: 38947.6
- 散金: 4908
- 红花: 88
- 沙发: 4
- 帖子: 11453
- 在线: 1355.6小时
- 虫号: 2739168
- 注册: 2013-10-20
- 性别: GG
- 专业: 一般管理理论与研究方法论
- 管辖: 论文翻译
2楼2014-04-26 20:53:46
